Inhibition of p53-mediated growth arrest by overexpression of cyclin- dependent kinases

Molecular and Cellular Biology

Volumn 16, Issue 8, 1996, Pages 4445-4455

  Latham, Kathryn M ^a   Eastman, Scott W ^a   Wong, Andrea ^a   Hinds, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH DISORDER; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; TEMPERATURE SENSITIVE MUTANT; TUMOR SUPPRESSOR GENE;

EID: 0029941446     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.8.4445     Document Type: Article

References (98)

1. ras mutants and c-ETS-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270: 23589-23597.
2. Baker, S. J., S. Markowitz, E. R. Fearon, J. K. V. Wilson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-918.
3. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (London) 377:552-557.
4. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
5. Chen, J., P. K. Jackson, M. W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (London) 374:386-388.
6. waf1/cip1, induces cyclin D1 synthesis. Cancer Res. 55:4257-4263.
7. Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (London) 362:849-852.
8. Cobrinik, D., S. F. Dowdy, P. W. Hinds, S. Mittnacht, and R. A. Weinberg. 1992. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem. Sci. 17:312-315.
9. Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7:546-554.
10. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
11. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (London) 356:215-221.
12. Dulic, V., W. K. Kaufman, S. J. Wilson, T. Tlsty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023.
13. Elbendary, A., A. Berchuck, P. Davis, L. Havrilesky, R. C. Bast, J. D. Iglehart, and J. R. Marks. 1994. Transforming growth factor beta-1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ. 5:1301-1307.
14. El-Deiry, W. S., J. W. Harper, P. M. O'Connor, V. E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietenpol, M. Burrell, D. E. Hill, Y. S. Wang, K. G. Wiman, W. E. Mercer, M. B. Kastan, K. W. Kohn, S. J. Elledge, K. W. Kinzler, and B. Vogelstein. 1994. Waf1/Cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169-1174.
15. El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
16. El-Deiry, W. S., T. Tokino, V. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
17. 1 cell-cycle arrest. Genes Dev. 9:204-217.
18. Ewen, M. E., H. K. Sluss, L. L. Whitehouse, and D. M. Livingston. 1993. TGFβ inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 74:1009-1020.
19. Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301-306.
20. Finlay, C. A., P. W. Hinds, T.-H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:531-539.
21. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53. Mol. Cell. Biol. 12:2866-2871.
22. Gao, X., Y. Q. Chen, N. Wu, D. J. Grignon, W. Sakr, A. T. Porter, and K. V. Honn. 1995. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395-1398.
23. Ginsberg, D., D. Michael-Michalovitz, D. Ginsberg, and M. Oren. 1991. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol. 11:582-585.
24. Gu, Y., C. W. Turck, and D. O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (London) 366:707-710.
25. Halevy, O., B. G. Novitch, D. B. Spicer, S. X. Skapek, J. Rhee, G. J. Hannon, D. Beach, and A. B. Lassar. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by myoD. Science 267:1018-1021.
26. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
27. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L. H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
28. He, J., J. R. Allen, V. P. Collins, M. J. Allalunis-Turner, R. Godbout, R. S. Day III, and C. D. James. 1994. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54:5804-5807.
29. Hermeking, H., and D. Eick. 1994. Mediation of c-myc-induced apoptosis by p53. Science 265:2091-2093.
30. Hermeking, H., J. O. Funk, M. Reichert, J. W. Ellwart, and D. Eick. Abrogation of p53-induced cell cycle arrest by c-myc - evidence for an inhibitor of p21(waf1/cip1/sdi1). Oncogene 11:1409-1415.
31. Hinds, P., C. Finlay, and A. Levine. 1989. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63:790-797.
32. Hinds, P. W. 1995. The retinoblastoma tumor suppressor protein. Curr. Opin. Genet. Dev. 5:79-83.
33. Hinds, P. W., S. Mittnacht, V. Dulic, A. Arnold, S. I. Reed, and R. A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
34. Hinds, P. W., and R. A. Weinberg. 1994. Tumor suppressor genes. Curr. Opin. Genet. Dev. 4:135-141.
35. Howes, K. A., L. N. Ransom, D. S. Papermaster, J. G. H. Lasudry, D. M. Albert, and J. J. Windle. 1994. Apoptosis or retinoblastoma - alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 8:1300-1310.
36. Hunter, T., and J. Pines. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
37. Jiang, H. P., J. Lin, Z. Z. Su, F. R. Collart, E. Huberman, and P. B. Fisher. 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21/WAF1/CIP1 expression in the absence of p53. Oncogene 9:3397-3406.
38. Johnson, M., D. Dimitrov, P. J. Vojta, J. C. Barrett, A. Noda, O. M. Pereira-Smith, and J. R. Smith. 1994. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol. Carcinog. 11:59-64.
39. Kastan, M. B., O. Onyinye, D. Sidransky, B. Vogelstein, and R. Craig. 1991. Participation of p53 in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
40. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-598.
41. Kato, J. Y., M. Matsuoka, D. K. Strom, and C. J. Sherr. 1994. Regulation of cyclin D-dependent kinase-4 (cdk4) by cdk4-activating kinase. Mol. Cell. Biol. 14:2713-2721.
42. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
43. Khatib, Z. A., H. Matsushime, M. Valentine, D. N. Shapiro, C. J. Sherr, and A. T. Look. 1993. Co-amplification of the CDK4 gene with MDM-2 and GL1 in human sarcomas. Cancer Res. 53:5535-5541.
44. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
45. Ladanyi, M., R. Lewis, S. C. Jhanwar, W. Gerald, A. G. Huvos, and J. H. Healey. 1995. MDM2 and CDK4 gene amplification in Ewing sarcoma. J. Pathol. 175:211-217.
46. Lin, H. J., V. Eviner, G. C. Prendergast, and E. White. 1995. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol. 15:4536-4544.
47. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
48. Lowe, S. W., and H. E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7:535-545.
49. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
50. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (London) 362:847-849.
51. Martinez, J., I. Georgoff, J. Martinez, and A. J. Levine. 1991. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5:151-159.
52. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J.-Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
53. Michael-Michalovitz, D., F. Yehiely, E. Gottlieb, and M. Oren. 1991. Simian virus 40 can overcome the antiproliferative effect of wild-type p53 in the absence of stable large T antigen-p53 binding. J. Virol. 65:4160-4168.
54. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680.
55. Michieli, P., M. Chedid, D. Lin, J. H. Pierce, W. E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:3391-3395.
56. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020.
57. Mittnacht, S., and R. A. Weinberg. 1991. G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65:381-393.
58. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
59. Morgan, D. O. 1995. Principles of CDK regulation. Nature (London) 374: 131-134.
60. Morgenbesser, S. D., B. O. Williams, T. Jacks, and R. A. DePinho. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (London) 371:72-74.
61. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre vetroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
62. Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:90-98.
63. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (London) 358:80-83.
64. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature (London) 362:857-860.
65. Pagano, M., R. Pepperkok, J. Lukas, V. Baldin, W. Ansorge, J. Bartek, and G. Draetta. 1993. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J. Cell Biol. 121:101-111.
66. Parker, S. B., G. Eichele, P. M. Zhang, A. Rawls, A. T. Sands, A. Bradley, E. N. Olson, J. W. Harper, and S. J. Elledge. 1995. p53-independent expression of p21/CIP1 in muscle and other terminally differentiating cells. Science 267:1024-1027.
67. Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. El-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91:1998-2002.
68. KIP1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22.
69. Kip1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
70. Quartin, R. S., C. N. Cole, J. M. Pipas, and A. J. Levine. 1994. The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells. J. Virol. 68:1334-1341.
71. Reynisdottir, I., K. Polyak, A. Iavarone, and J. Massagué. 1995. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9:1831-1845.
72. Sabbatini, P., J. Lin, A. J. Levine, and E. White. 1995. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9:2184-2192.
73. Schmidt, E. E., K. Ichimura, G. Reifenberger, and V. P. Collins. 1994. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:6321-6324.
74. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581-5592.
75. Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551-555.
76. Shiohara, M., W. S. El-Deiry, M. Wada, T. Nakamaki, S. Takeuchi, R. Yang, D. L. Chen, B. Vogelstein, and H. P. Koeffler. 1994. Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784.
77. Spitkovsky, D., P. Steiner, R. V. Gopalkrishnan, M. Eilers, and P. Jansen-Durr. 1995. The role of p53 in coordinated regulation of cyclin D1 and p21 gene expression by the adenovirus E1A and E1B oncogenes. Oncogene 10:2421-2425.
78. Steinman, R. A., B. Hoffman, A. Iro, C. Guillouf, D. A. Liebermann, and M. E. Elhouseini. 1994. Induction of WAF1/CIP1 during differentiation. Oncogene 9:3389-3396.
79. Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711.
80. Thut, C. J., J. L. Chen, R. Klemm, and R. Tjian. 1995. P53 transcriptional activation mediated by coactivators TAF(11)40 and PAF(11)60. Science 267: 100-104.
81. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74.
82. Tsai, L.-H., E. Lees, B. Faha, E. Harlow, and K. Riabowol. 1993. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8:1593-1602.
83. van den Heuvel, S., and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050-2054.
84. Vousden, K. H., B. Vojtesek, C. Fisher, and D. Lane. 1993. HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 8:697-702.
85. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (London) 369:574-578.
86. Wagner, A. J., J. M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21(waf1/cip1). Genes Dev. 8:2817-2830.
87. 1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
88. Whyte, P., K. J. Buchkovich, J. M. Horowitz, S. H. Friend, M. Raybuck, R. A. Weinberg, and E. Harlow. 1988. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (London) 334:124-129.
89. Williams, B. O., L. Remington, D. M. Albert, S. Mukai, R. T. Bronson, and T. Jacks. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet. 7:480-484.
90. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
91. Wong, A., and P. Hinds. Unpublished observations.
92. Wu, X. W., and A. J. Levine. 1994. p53 and E2F cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91:3602-3606.
93. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature (London) 366: 701-704.
94. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357: 82-85.
95. Yewdell, J. W., J. V. Cannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444-452.
96. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplifications in cells with mutant p53 alleles. Cell 70:937-948.
97. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.
98. Zhu, L., E. Harlow, and B. Dynlacht. 1995. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev. 9:1740-1752.